Centessa Pharmaceuticals PLC ADR - Asset Resilience Ratio
Centessa Pharmaceuticals PLC ADR (CNTA) has an Asset Resilience Ratio of 33.37% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Centessa Pharmaceuticals PLC ADR strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Centessa Pharmaceuticals PLC ADR's Asset Resilience Ratio has changed over time. See how leveraged is Centessa Pharmaceuticals PLC ADR's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Centessa Pharmaceuticals PLC ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Centessa Pharmaceuticals PLC ADR market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $214.16 Million | 33.37% |
| Total Liquid Assets | $214.16 Million | 33.37% |
Asset Resilience Insights
- Very High Liquidity: Centessa Pharmaceuticals PLC ADR maintains exceptional liquid asset reserves at 33.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Centessa Pharmaceuticals PLC ADR Industry Peers by Asset Resilience Ratio
Compare Centessa Pharmaceuticals PLC ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Centessa Pharmaceuticals PLC ADR (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Centessa Pharmaceuticals PLC ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 33.93% | $233.28 Million | $687.50 Million | +16.78pp |
| 2024-12-31 | 17.16% | $98.96 Million | $576.80 Million | -18.52pp |
| 2023-12-31 | 35.68% | $128.52 Million | $360.25 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $444.31 Million | -- |
About Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as we… Read more